A well-designed clinical trial to assess the efficacy of necroptosis inhibitors in the management of ITP patients is highly recommended, as are additional studies on a larger cohort of ITP patients to validate our suggestions for the use of MLKL, RIPK3 and Beclin-1 as promising markers for prediction of bleeding severity and treatment response in ITP patients. This evidence concerns the gene BECN1 and autoimmune thrombocytopenic purpura.